Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | BCL9 | O00512 | 1/20 | 0.52 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | FAAH | O00519 | 2/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.45 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.45 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | MYOC | Q99972 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11410802 | 0.89 | MGLL (0.55) | MGLLMAPTBCL9CTNNB1GAA | |
| SCHEMBL29708171 | 0.85 | MGLL (0.64) | MGLLMAPTBCL9CTNNB1GAA | |
| SCHEMBL25191223 | 0.83 | MGLL (0.70) | MGLLBCL9CTNNB1GAAFAAH | |
| 4-Nitrophenyl Ethylcarbamate SCHEMBL1695035 | 0.83 | MGLL (0.74) | MGLLMAPTBCL9CTNNB1GAA | |
| SCHEMBL18703462 | 0.83 | MGLL (0.78) | MGLLMAPTBCL9CTNNB1GAA | |
| SCHEMBL14617269 | 0.81 | MGLL (0.84) | MGLLMAPTBCL9CTNNB1GAA | |
| SCHEMBL19412173 | 0.80 | MGLL (0.84) | MGLLBCL9CTNNB1GAAFAAH | |
| SCHEMBL3398600 | 0.80 | MGLL (0.65) | MGLLMAPTBCL9CTNNB1GAA | |
| SCHEMBL10964677 | 0.80 | ALDH1A1 (0.50) | MAPTGAARAB9AALDH1A1MAPK1 | |
| SCHEMBL14297325 | 0.80 | SMN1; SMN2 (0.50) | MGLLGAAKMT2ASMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210284668-A1 | GOLD (I)-PHOSPHINE 1,2,3-TRIAZOLE DERIVATIVES WITH ANTIBIOTIC PROPERTIES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2021-09-16 | — | — | US | disclosed |
| WO-2019243273-A1 | GOLD (I)-PHOSPHINE 1,2,3-TRIAZOLE DERIVATIVES WITH ANTIOBIOTIC PROPERTIES | UNIVERSITÉ DE STRASBOURG (FR) | 2019-12-26 | — | — | WO | disclosed |
| EP-1528925-B1 | QUINAZOLINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2009-04-22 | — | — | EP | disclosed |
| US-7504408-B2 | Quinzoline derivatives for use in the treatment of cancer | ASTRAZENECA AB (SE) | 2009-03-17 | — | — | US | disclosed |
| US-7179907-B2 | Antibiotic compounds | SOMALOGIC OPERATING CO. INC. | 2007-02-20 | — | — | US | disclosed |
| US-7157457-B2 | Compounds useful in the treatment of inflammatory diseases | GLAXO GROUP LIMITED (GB) | 2007-01-02 | — | — | US | disclosed |
| EP-1324991-B1 | COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES | GLAXO GROUP LTD (GB) | 2006-11-15 | — | — | EP | disclosed |
| US-20050250797-A1 | Quinzoline derivatives for use in the treatment of cancer | ASTRAZENECA AB (SE) | 2005-11-10 | — | — | US | disclosed |
| EP-1586567-A1 | Compounds useful in the treatment of inflammatory diseases | GLAXO GROUP LIMITED (GB) | 2005-10-19 | — | — | EP | disclosed |
| US-20050124598-A1 | Antibiotic compounds | EC TECHNOLOGY, LLC (US) | 2005-06-09 | — | — | US | disclosed |
| EP-1528925-A1 | QUINAZOLINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | Astrazeneca AB (SE) | 2005-05-11 | — | — | EP | disclosed |
| US-20040058907-A1 | Compounds useful in the treatment of inflammatory diseases | GLAXO GROUP LIMITED (GB) | 2004-03-25 | — | — | US | disclosed |
| WO-2004004732-A1 | QUINAZOLINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2004-01-15 | — | — | WO | disclosed |
| EP-1324991-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2003-07-09 | — | — | EP | disclosed |
| WO-2003051314-A2 | ANTIBIOTIC COMPOUNDS | MEDALLION BIOMEDICAL, LLC (US) | 2003-06-26 | — | — | WO | disclosed |
| WO-2002026723-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2002-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210284668-A1 | GOLD (I)-PHOSPHINE 1,2,3-TRIAZOLE DERIVATIVES WITH ANTIBIOTIC PROPERTIES | PADI3, PADI1, PADI4 | MGLL 3818/4885MAPT 2449/4885BCL9 3931/4885 |
| US-20050124598-A1 | Antibiotic compounds | RNGTT, BCDIN3D, COASY | MGLL 1385/4885MAPT 4119/4885BCL9 3698/4885 |
| US-20040058907-A1 | Compounds useful in the treatment of inflammatory diseases | TNF, IL1B, IL4 | MGLL 3146/4885MAPT 3346/4885BCL9 1009/4885 |
| US-20050250797-A1 | Quinzoline derivatives for use in the treatment of cancer | TPD52L2, NQO2, CCNI | MGLL 4842/4885MAPT 4425/4885BCL9 1431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.